https://doi.org/10.1097/qai.0000000000002731
D
Debbie Hagins
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
45
Papers
2.6K
Citations
21
h-index
27
i10-index
Debbie Hagins is an academic researcher from Coastal Health District. The author has contributed to research in topics: HIV/AIDS drug development and treatment & HIV Research and Treatment & HIV/AIDS Research and Interventions. The author has an h-index of 21, co-authored 39 publications.
ORCID: 0000-0001-7478-7609Papers by this author
worksSwitching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study
2021 · JAIDS Journal of Acquired Immune Deficiency Syndromes · 39 citations
High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I
2022 · AIDS · 36 citations
https://doi.org/10.1097/qad.0000000000003244
DEFINE: A Prospective, Randomized, Phase 4 Trial to Assess a Protease Inhibitor–Based Regimen Switch Strategy to Manage Integrase Inhibitor–Related Weight Gain
2024 · Clinical Infectious Diseases · 12 citations
https://doi.org/10.1093/cid/ciae449
Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals
2021 · Patient · 7 citations
https://doi.org/10.1007/s40271-021-00534-y
Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV
2025 · AIDS Research and Therapy · 2 citations
https://doi.org/10.1186/s12981-025-00732-w
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat